HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Inhibition of contact sensitivity in human CD4+ transgenic mice by human CD4-specific monoclonal antibodies: CD4+ T-cell depletion is not required.

Abstract
Clenoliximab and keliximab are monkey/human chimeric monoclonal antibodies (mAbs) of the immunoglobulin G4 (IgG4) and IgG1 isotypes, respectively, that recognize the same epitope on human CD4. The two mAbs possess identical idiotypes and exhibit equal affinities for CD4. Upon administration of these mAbs to mice that express a human CD4 transgene, but not mouse CD4 (HuCD4/Tg mice), clenoliximab and keliximab exhibited similar kinetics of binding to CD4, and induced the same degree of CD4 modulation from the cell surface, although only keliximab mediated CD4+ T-cell depletion. Epicutaneous sensitization and challenge of HuCD4/Tg mice with the hapten oxazolone resulted in a contact sensitivity response characterized by tissue swelling, and the presence of interferon-gamma (IFN-gamma) and interleukin-4 (IL-4) in the local tissue. Administration of a single 2-mg dose of either clenoliximab or keliximab to HuCD4/Tg mice prior to sensitization significantly reduced post-challenge tissue swelling, and levels of IFN-gamma and IL-4, indicating that CD4+ T-cell depletion is not required for anti-CD4 mAb-mediated inhibition of contact sensitivity. Administration of either mAb prior to challenge failed to inhibit the contact sensitivity response, indicating differential sensitivity of the afferent and efferent phases of the response to inhibition by CD4-specific mAbs. Collectively, these data indicate that CD4 functions as a positive regulatory molecule in the contact sensitivity response.
AuthorsP L Podolin, E F Webb, M Reddy, A Truneh, D E Griswold
JournalImmunology (Immunology) Vol. 99 Issue 2 Pg. 287-95 (Feb 2000) ISSN: 0019-2805 [Print] England
PMID10692049 (Publication Type: Journal Article)
Chemical References
  • Adjuvants, Immunologic
  • Antibodies, Monoclonal
  • CD4 Antigens
  • clenoliximab
  • keliximab
  • Oxazolone
  • Interleukin-4
  • Interferon-gamma
Topics
  • Adjuvants, Immunologic
  • Animals
  • Antibodies, Monoclonal (immunology, metabolism)
  • CD4 Antigens (metabolism)
  • CD4-Positive T-Lymphocytes (immunology)
  • Dermatitis, Contact (immunology)
  • Dose-Response Relationship, Immunologic
  • Humans
  • Immune Tolerance
  • Interferon-gamma (metabolism)
  • Interleukin-4 (metabolism)
  • Mice
  • Mice, Transgenic
  • Oxazolone (immunology)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: